Physician profile
Joel D Quist
NPI 1134415789
$1,160.36
in general payments reported to CMS, 2019-2025
11 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.23 · 2020: $522 · 2021: $84.56 · 2022: $63.21 · 2023: $77.30 · 2024: $221 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| The Walman Optical Company | $480.00 | 2020 | |
| Coopervision INC. | $174.10 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $167.04 | 2020-2025 | |
| Alcon Vision LLC | $108.51 | 2022-2024 | Total30, Precision 1 |
| Glaukos Corporation | $90.42 | 2024 | Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $34.61 | 2024-2025 | Xdemvy |
| Allergan, INC. | $28.34 | 2019-2021 | |
| Abbvie INC. | $25.69 | 2023 | |
| Dompe US, INC. | $21.10 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $15.73 | 2021 | |
| Bausch & Lomb Americas INC. | $14.82 | 2024 | Xiidra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.